Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.0112.01%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -119.99% | -128.16% | -94.30% | -53.53% | 4.49% |
| Total Depreciation and Amortization | -77.27% | -57.95% | -38.64% | -19.32% | 2.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,617.09% | 3,784.73% | 3,245.15% | 2,667.08% | -1.27% |
| Change in Net Operating Assets | 2,632.49% | 436.10% | 261.14% | -69.80% | -88.63% |
| Cash from Operations | -14.83% | 1.39% | -11.38% | -27.69% | -6.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -18.72% | -20.73% | -17.69% | 15.27% | -8.58% |
| Total Debt Repaid | 36.77% | 27.38% | 22.25% | -42.94% | -19.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 30.82% | 22.23% | 23.72% | 25.38% | -12.30% |
| Foreign Exchange rate Adjustments | 98.31% | 100.45% | 99.57% | 96.72% | -7,966.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.93% | 77.54% | 47.49% | -32.62% | -164.28% |